Home > Insider Trading > Filing (0000899243-21-007444)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1656536	Decibel Therapeutics Inc.	DBTX	Pharmaceutical Preparations (2834)	464198709

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1842129	Matthew Foy	C/O Decibel Therapeutics, Inc. 1325 Boylston Street, Suite 500 Boston MA 02215		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-02-17	458,487	$0.00	458,487	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-02-17	247,324	$0.00	705,811	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-02-17	327,852	$0.00	1,033,663	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-02-17	150,000	$18.00	1,183,663	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2021-02-17	7,119,852	$0.00	458,487	$0.00
Common Stock	Series C Preferred Stock	Disposition	2021-02-17	3,125,000	$0.00	247,324	$0.00
Common Stock	Series D Preferred Stock	Disposition	2021-02-17	1,737,619	$0.00	327,852	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

On February 17, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 15.529-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
On February 17, 2021, the Series C Preferred Stock automatically converted into Common Stock on a 12.6352-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
On February 17, 2021, the Series D Preferred Stock automatically converted into Common Stock on a 5.3-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
Held of record by GSK Equity Investments, Limited ("GSK"), an indirect, wholly owned subsidiary of GlaxoSmithKline plc. SR One Capital Management, LP ("S.R. One") is the investment advisor for GSK. Mr. Foy is a partner at S.R. One. Mr. Foy disclaims beneficial ownership of all the shares reported herein and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his proportionate pecuniary interest therein.